Authors: Venza, I Giordano, L Piraino, G Medici, N Ceci, G Teti, D

Citation: I. Venza et al., Prostaglandin E2 signalling pathway in human T lymphocytes from healthy and conjunctiva basal cell carcinoma-bearing subjects, IMM CELL B, 79(5), 2001, pp. 482-489

Authors: Cocconi, G Bella, M Lottici, R Leonardi, F Ceci, G Passalacqua, R Di Blasio, B Bordi, C Biscottini, B Melpignano, M De Biasi, D Finardi, C Bacchi, M

Citation: G. Cocconi et al., Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma, AM J CL ONC, 22(6), 1999, pp. 559-567

Authors: Cocconi, G Bisagni, G Ceci, G Blasio, BD De Lisi, V Passalacqua, R Zadro, A Boni, C Morandi, P Savoldi, L

Citation: G. Cocconi et al., Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial, BREAST CANC, 56(2), 1999, pp. 125-132

Authors: Boni, C Savoldi, L Bisagni, G Ceci, G Crino, L De Lisi, V Di Costanzo, F Lasagni, L Manenti, AL Moretti, G Rondini, E Sassi, M Zadro, A

Citation: C. Boni et al., Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): A phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC), EUR J CANC, 34(12), 1998, pp. 1974-1976